The bone marrow-mediated protection of myeloproliferative neoplastic cells to Vorinostat and Ruxolitinib relies on the activation of JNK and PI3K signalling pathways

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
10 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The bone marrow-mediated protection of myeloproliferative neoplastic cells to Vorinostat and Ruxolitinib relies on the activation of JNK and PI3K signalling pathways'. Together they form a unique fingerprint.

Medicine & Life Sciences